Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 15/20 | 0.56 |
| ▸ | CA2 | P00918 | 15/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247263 | 0.87 | CA1 (0.60) | ALDH1A1HTTCA1CA2MAPT | |
| SCHEMBL14419572 | 0.85 | CA1 (0.56) | HTTCA1CA2CA9POLB | |
| SCHEMBL14419567 | 0.85 | CA1 (0.57) | HTTCA1CA2CA9POLB | |
| SCHEMBL248505 | 0.84 | CA1 (0.78) | CA1CA2CA9CA12CA5A | |
| SCHEMBL2639424 | 0.81 | CA1 (0.71) | ALDH1A1HTTCA1CA2CA9 | |
| SCHEMBL10682779 | 0.78 | ALDH1A1 (0.71) | ALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL29643255 | 0.78 | SMN1; SMN2 (1.00) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4228749 | 0.78 | SMN1; SMN2 (1.00) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL22196908 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HTTCA1CA2MAPT | |
| SCHEMBL16176772 | 0.77 | CA2 (0.59) | HTTCA1CA2CA9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8481581-B2 | S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2609917-A1 | Triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2402011-B1 | S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252828-B2 | S-triazolyl α-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2353593-B1 | Non-nucleoside reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2012-08-22 | — | — | EP | disclosed |
| CN-101083987-A | S-triazolyl alpha-mercaptoacetanilides as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2007-12-05 | — | — | CN | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| EP-1789039-A2 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Ardea Biosciences, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | INTRABIOTICS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006026356-A2 | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| CN-1697650-A | Non-nucleoside reverse transcriptase inhibitors | RIBAPHARM INC (US) | 2005-11-16 | — | — | CN | disclosed |
| EP-1545483-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Ribapharm Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004030611-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RIBAPHARM INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | ALDH1A1 1407/4885HTT 3263/4885SMN1; SMN2 2651/4885 |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | ALDH1A1 1407/4885HTT 3263/4885SMN1; SMN2 2651/4885 |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, TYMP, RNGTT | ALDH1A1 271/4885HTT 2326/4885SMN1; SMN2 1681/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | ALDH1A1 1407/4885HTT 3263/4885SMN1; SMN2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.